Azathioprine. Azathioprine is an effective disease modifying drug used in the treatment of inflammatory arthritis, inflammatory bowel disease, lupus and other inflammatory conditions. It has immunosuppressant and anti-inflammatory effects.
Azathioprine. In general, starting dosage is from 1mg/kg body weight/day, increasing after 4-6 weeks to 2- 3mg/kg/day, depending on the clinical response (which may not be evident for weeks or months) and haematological tolerance
Azathioprine. Patients should have baseline thiopurine methyltransferase (TPMT) status assessed. Patients should have formal ophthalmic examination with their optician annually. This should include formal visual acuity testing for distance and reading vision, fundoscopy and 10-2 central visual field testing. If a patient is on Hydroxychloroquine for > 5years, the patient should be referred to ophthalmology for the above tests and in addition have an objective retinal assessment for using optical coherence tomography (OCT).
Azathioprine. (Imuran®) ICB As a steroid-sparing effect in patients with Autoimmune Diseases in whom steroids cannot be reduced or are contraindicated, and for maintaining remission in vasculitis Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. AMB 2 Azathioprine (Generics are available) ICB Steroid-sparing effect in ulcerative colitis and Crohn's disease (Not a licensed indication). Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Hospital Azelastine and Fluticasone nasal spray Dymista® ICB moderate to severe seasonal and perennial rhinitis if monotherapy with antihistamine or corticosteroid is inadequate Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Azilsartan (Edarbi®)
Azathioprine. (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus / dermatomyositis, polymyositis and pemphigus vulgaris This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of azathioprine in systemic lupus erythematosus / dermatomyositis and polymyositis can be shared between the specialist and general practitioner (GP). You are invited to participate however, if you do not feel confident to undertake this role, then you are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care will be explained to the patient by the specialist initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients with systemic lupus erythematosus / dermatomyositis and polymyositis are usually under regular specialist follow-up, which provides an opportunity to discuss drug therapy.
Azathioprine. For the treatment of systemic lupus erythematosus / dermatomyositis and polymyositis / pemphigus vulgaris Please refer to BSSE APC formulary website for complete document.
Azathioprine. ESCA: For the treatment of rheumatoid arthritis or psoriatic arthritis This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of azathioprine for rheumatoid arthritis or psoriatic arthritis can be shared between the specialist and general practitioner (GP). You are invited to participate however, if you do not feel confident to undertake this role, then you are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care will be explained to the patient by the specialist initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients with rheumatoid arthritis or psoriatic arthritis are usually under regular specialist follow-up, which provides an opportunity to discuss drug therapy.
Azathioprine. ESCA: For the treatment of Auto immune haemolytic anaemia This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of Azathioprine in auto immune haemolytic anaemia can be shared between the specialist and general practitioner (GP). You are invited to participate however, if you do not feel confident to undertake this role, then you are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care will be explained to the patient by the specialist initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients with haemolytic anaemia are usually under regular specialist follow-up, which provides an opportunity to discuss drug therapy. An ESCA is not necessarily required retrospectively for patients who have already previously been prescribed a medication in primary care for a period greater than one year, or who were prescribed a medication prior to the existence of the ESCA. Any referral back to the specialist in these circumstances should be based on clinical need. EMIS and Vision 8BM5.00 415522008 Shared care prescribing
Azathioprine. For the treatment of auto-immune haemolytic anaemia
Azathioprine. (Imuran®) ICB As a steroid-sparing effect in patients with Autoimmune Diseases in whom steroids cannot be reduced or are contraindicated, and for maintaining remission in vasculitis Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. AMB 2 Azathioprine (Generics are available) ICB Steroid-sparing effect in ulcerative colitis and Crohn's disease (Not a licensed indication).
